Android app on Google Play

Tranzyme (TZYM) Closes 3M Direct Offering at $3.85/Share

September 18, 2012 4:33 PM EDT Send to a Friend
Tranzyme Pharma (Nasdaq: TZYM) has closed the previously announced underwritten registered direct offering of approximately 3.0 million shares of its common stock at a price of $3.85 per share for gross proceeds, including the over-allotment option, of approximately $11.5 million. The shares include approximately 0.4 million shares of common stock sold pursuant to the over-allotment option granted by the Company to the underwriters, which option was exercised in full. The net proceeds from the sale of the shares, after deducting the underwriters' discounts and other estimated offering expenses payable by Tranzyme, will be approximately $10.6 million. The Company intends to use the proceeds for working capital and other general corporate purposes.

Cowen and Company, LLC acted as sole bookrunning manager for the offering. JMP Securities LLC acted as a co-manager for the offering.




You May Also Be Interested In


Related Categories

Corporate News, Equity Offerings

Related Entities

JMP Securities, Cowen & Co

Add Your Comment